Features | Partner Sites | Information | LinkXpress
Sign In
SIEMENS DIAGNOSTICS

Meta-Analysis Finds Home-Based Test Effective for Colorectal Cancer Screening

By Labmedica International staff writers
Posted on 10 Feb 2014
Image: Patient-friendly fecal immunochemical tests (FITs) – effective tool for colorectal cancer screening (Photo courtesy of Kaiser Permanente).
Image: Patient-friendly fecal immunochemical tests (FITs) – effective tool for colorectal cancer screening (Photo courtesy of Kaiser Permanente).
The largest and most comprehensive evidence review to date indicates that the patient-friendly and simple home-based test is a valuable colorectal cancer-screening tool.

Tests that require patients to collect a single stool sample at home and then send it to a lab for analysis detect about 79% of colorectal cancers (CRCs), according to a new evidence review now published by Lee, et al. in the journal Annals of Internal Medicine, February 4, 2014. The review of 19 studies examining eight different fecal immunochemical tests (FITs) also finds that such tests will correctly identify about 94% of patients who do not have cancers of the rectum or colon. "Now we also know that [FIT] is a great tool for assessing which patients have [this] cancer and which patients don’t,” said Beth Liles, MD, clinical investigator at the Kaiser Permanente Center for Health Research in Portland (OR, USA) of Kaiser Permanente (Oakland, CA, USA).

“The American Cancer Society and other professional organizations have recommended FIT as a screening tool for CRC since 2008, but there are still many people who don’t know about it,” said Jeffrey Lee, MD, MAS, and postdoctoral researcher at the Kaiser Permanente Division of Research and at the University of California, San Francisco. Unlike older stool tests, FIT does not require people to restrict their diets or to stop taking medications. Conducted annually, FIT detects small amounts of blood in the stool; people who test positive are much more likely to have CRC and so would need a follow-up colonoscopy.

The evidence review found that the FITs were fairly sensitive. On average, the tests detected 79% of CRCs with only one round of testing. The tests were also highly specific: on average, 94% of people who did not have cancer tested negative with a single FIT. By comparison, studies indicate that the at-home fecal occult blood test (FOBT) test, which requires 3 stool samples as well as medication and dietary restrictions, detects only about 13% to 50% of CRCs after a single round of testing.

According to the review, no single FIT performed markedly better than another, but the authors caution that there was only one study comparing brands head-to-head. Most of the FITs required collection of only one stool sample. Surprisingly, brands requiring two or three stool samples were no more accurate than those requiring only one.

The 19 studies included 80 to 27,860 patients, with the average age ranging from 45 to 63. Study settings varied. Eligibility criteria were to include all studies evaluating the diagnostic accuracy of FITs for CRC in asymptomatic, average-risk adults. The review was limited to studies in the English language. Two reviewers independently extracted data and critiqued study quality. In 12 of the studies, all patients took the FIT and received a colonoscopy. In seven studies, patients only had a colonoscopy to follow-up on a positive FIT. Approximately 2 years later, researchers followed up with patients who had had a negative FIT to determine whether they had been diagnosed with CRC.

FITs were concluded to be moderately sensitive, highly specific, and with high overall diagnostic accuracy for detecting CRC. Sensitivity for CRC improved with lower assay cutoff values for a positive test result but with a corresponding decrease in specificity. The study was part of Kaiser Permanente’s ongoing efforts to promote prevention and evidence-based care. Another Kaiser Permanente study also found that patients who visited their doctor for any reason were nearly 6 times more likely to be screened for CRC compared to those who did not visit their doctor.

Related Links:

Kaiser Permanente
Kaiser Permanente Division of Research



Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.